This is not the most recent version of the article. View current version (9 JUL 2014)

Intervention Protocol

Adjunctive antithyroid drugs in radioiodine therapy for hyperthyroidism

  1. Tarun Singhal1,*,
  2. Siddharth Bansal2,
  3. Aparna Singhal3,
  4. Stephen McDonald4,
  5. Chandra S Bal5

Editorial Group: Cochrane Metabolic and Endocrine Disorders Group

Published Online: 20 JUL 2005

Assessed as up-to-date: 23 MAY 2005

DOI: 10.1002/14651858.CD005447


How to Cite

Singhal T, Bansal S, Singhal A, McDonald S, Bal CS. Adjunctive antithyroid drugs in radioiodine therapy for hyperthyroidism (Protocol). Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD005447. DOI: 10.1002/14651858.CD005447.

Author Information

  1. 1

    Yale-New Haven Hospital, Department of Internal Medicine, New Haven, Connecticut, USA

  2. 2

    University of California, Los Angeles, Occupational and Environmental (Preventive) Medicine/Family medicine, Los Angeles, California, USA

  3. 3

    University of California Los Angeles, Radiological Sciences, Los Angeles, USA

  4. 4

    Kettering Medical Center, Internal Medicine and Endocrinology, Kettering, Ohio, USA

  5. 5

    All India Institute of Medical Sciences, Ansari Nagar, Nuclear Medicine and P.E.T., New Delhi, India

*Tarun Singhal, Department of Internal Medicine, Yale-New Haven Hospital, 333 Cedar Street, New Haven, Connecticut, CT-06511, USA. t_singhal@hotmail.com.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 20 JUL 2005

SEARCH

This is not the most recent version of the article. View current version (09 JUL 2014)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The main objectives of the review are:

  • to determine the safety and effects of therapy when antithyroid drugs, carbimazole, methimazole, or propylthiouracil are used before administering radioiodine for treating hyperthyroidism as compared to radioiodine without antithyroid drugs.
  • to determine the safety and effects of therapy when antithyroid drugs, carbimazole, methimazole, or propylthiouracil are used after administering radioiodine for treating hyperthyroidism as compared to radioiodine without antithyroid drugs.
  • to determine the safety and effects of therapy when antithyroid drugs, carbimazole, methimazole, or propylthiouracil are used both before and after administering radioiodine for treating hyperthyroidism as compared to radioiodine without antithyroid drugs, and to antithyroid drugs with radioiodine when antithyroid drugs are given only before, or only after administering radioiodine.

The main outcomes of interest are cure, occurrence of thyrotoxic crisis and adverse cardiovascular events(as defined below) following therapy.